Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Item
http://www.wikidata.org/entity/Q37681170
Changing strategies for target therapy in gastric cancerLapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials.Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.Simultaneous targeting of estrogen receptor and HER2 in breast cancer.Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.Emerging EGFR antagonists for breast cancer.Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.Novel Systemic Therapies for Advanced Gastric Cancer.
P2860

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Item
http://www.wikidata.org/entity/Q37681170
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@en
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@nl
type
label
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@en
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@nl
prefLabel
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@en
Lapatinib and HER2 status: res ...... s in metastatic breast cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Lapatinib and HER2 status: res ...... ls in metastatic breast cancer
@en
P2093
P304
P31
P356
10.1016/J.CTRV.2009.12.012
P433
P478
P50
P577
P698
P921